Medexus Pharmaceuticals, Inc. Medexus Pharmaceuticals, Inc.

Investor Relations

Latest News

View Press Release
View All News

Treosulfan Pivotal Study Results with Dr. Filippo Milano, MD

Latest Financial Results

Q3 2023

Quarter Ended Dec 31, 2022
Earnings Release
PDF HTML
Audio
Earnings Webcast
Management Discussion & Analysis
PDF
Financial Statements
PDF

Email Alerts

Receive updates straight into your inbox

Sign up Today

Investor Contact Information

Company

Medexus Pharmaceuticals, Inc.
35 Nixon Rd Unit 1
Bolton, ON L7E 1K1
Canada

Investor Relations (Canada)

Adelaide Capital
Victoria Rutherford
T: 480-625-5772
Victoria@adcap.ca

Direct Financial Strategies and Communication Inc.
Frank Candido
T: 514-969-5530
frank.candido@medexus.com

Company Overview

Medexus Pharmaceuticals, Inc. is a leading innovative and rare disease pharmaceutical company with a strong North American commercial platform. The Company’s vision is to provide the best healthcare products to healthcare professionals and patients, through our core values of Quality, Innovation, Customer Service and Collaboration. Medexus is focused on the therapeutic areas of rheumatology, auto-immune disease, specialty oncology and pediatrics. The leading prescription products are Rasuvo and Metoject, a unique formulation of methotrexate (auto-injector and pre-filled syringe) designed to treat rheumatoid arthritis and other auto-immune diseases; and Rupall, an innovative allergy medication with a unique mode of action.